EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions

Annelyn Torres-Reveron iD, Jaydie M Valles Ortiz, Myrella L Cruz, Omar Velez-Lopez, Idhaliz Flores iD, Caroline B Appleyard

Biology of Reproduction · 18.08.2026 · 115 (2) · 500-514

DOI: 10.1093/biolre/ioag107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biology of Reproduction, online erschienen am 22.05.2026. Verfasst von Annelyn Torres-Reveron und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sur180 Therapeutics, INC., Research Division, McAllen, TX 78504, USA. Hauptthemen laut MEDLINE: Endometriosis, Receptors, Corticotropin-Releasing Hormone, Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, EnTrust Grant from the Puerto Rico Science and Technology Research Trust, NIH-NICHD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 (CRHR1) levels in endometriotic lesions in a rat model. Here, we tested the hypothesis that antagonizing CRHR1 with pexacerfont, an orally bioavailable small-molecule antagonist, would reduce endometriosis-associated pain and lesion activity. Beginning 25 days after disease induction, rats received pexacerfont (10 mg/kg), vehicle, or elagolix (14 mg/kg) in 7-day treatment cycles separated by 7-day drug-free intervals up to day 60 after endometriosis onset. Pexacerfont significantly reduced mechanical and inflammatory pain (34% and 38% decreases, respectively) and decreased nerve growth factor, vascular endothelial growth factor, Ki67, and IL-6 and TNF-α mRNA expression within lesions. Unlike elagolix, pexacerfont did not alter peritoneal leptin-to-weight or serum FSH-to-LH ratios, indicating minimal disruption of gonadal endocrine signaling. Notably, pexacerfont reduced macroscopic adhesion scores by half, a therapeutic effect not observed with either vehicle or elagolix. CRHR1 antagonism, therefore, suppressed neuro-inflammatory and proliferative pathways while limiting lesion-associated angiogenesis and postoperative adhesion development. These findings position CRHR1 as a mechanistically distinct, non-hormonal therapeutic target for endometriosis and highlight pexacerfont’s potential to reduce both pain and adhesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndometriosisReceptors, Corticotropin-Releasing HormonePainAnimalsFemaleCRF Receptor, Type 1RatsPyrimidinesTissue AdhesionsRats, Sprague-DawleyAdministration, OralHydrocarbons, FluorinatedAniline Compounds

Stichwörter der Autor:innen

corticotropinnon-endocrinetreatment

Substanzen

Receptors, Corticotropin-Releasing HormoneCRF Receptor, Type 1Pyrimidines2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidineelagolixHydrocarbons, FluorinatedAniline Compounds

Autor:innen und Institutionen

  • Sur180 Therapeutics, INC., Research Division, McAllen, TX 78504, USA.
  • Basic Sciences Department, Ponce Research Institute, Ponce Health Sciences University, Ponce, PR 00716, USA.
  • School of Dental Medicine, Ponce Research Institute, Ponce Health Sciences University, Ponce, PR 00716, USA.

ORCID-Profile: Annelyn Torres-Reveron, Idhaliz Flores

Förderung

  • NICHD NIH HHS
  • EnTrust Grant from the Puerto Rico Science and Technology Research Trust
  • NIH-NICHD

Zitieren

APA

Torres-Reveron, A., Valles Ortiz, J. M., Cruz, M. L., Velez-Lopez, O., Flores, I., & Appleyard, C. B. (2026). Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions. Biology of Reproduction, 115(2), 500-514. https://doi.org/10.1093/biolre/ioag107

Vancouver

Torres-Reveron A, Valles Ortiz JM, Cruz ML, Velez-Lopez O, Flores I, Appleyard CB. Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions. Biology of Reproduction. 2026;115(2):500-514. doi:10.1093/biolre/ioag107

BibTeX
@article{TorresReveron2026,
  author = {Torres-Reveron, Annelyn and Valles Ortiz, Jaydie M and Cruz, Myrella L and Velez-Lopez, Omar and Flores, Idhaliz and Appleyard, Caroline B},
  title = {Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions},
  journal = {Biology of Reproduction},
  year = {2026},
  volume = {115},
  number = {2},
  pages = {500--514},
  doi = {10.1093/biolre/ioag107}
}
Kostenlos starten →